Lupus or systemic lupus erythematosus is a chronic autoimmune disease with systemic inflammation manifestations mainly in targeted organs. The appropriate animal model for lupus is necessary. The induction method by using 2,6,10,14 tetramethylpentadecane (TMPD) reveals more complex manifestations than other hydrocarbons. However, the autophagy of macrophages as an effect of TMPD makes differences to make the decision in lupus biomarker as a targeted therapy in lupus arthritis. Thus, this research focused on the role of CD68+IL-6 produced by macrophages and total IL-6 in lupus in correlation to the arthritis severity. The naïve and TMPD-treated groups (n=3) were induced by means of 0.5 ml TMPD i.p.
Introduction
The animal model for lupus arthritis is rarely studied. Hydrocarbons like complete Fre- VMIC 2017 the immunity of experimental animal used [1, 2] . TMPD reveals more complex manifestations which the joint disorder occurs as a result of systemic immune imbalance.
TMPD stimulates the production of IFN-α and IFN-through immature monocytes (Ly6Chi). The production of IFN-I and pro-inflammatory cytokines could be stimulated by four main cell pathways by utilizing the differences between adaptor proteins or signaling intermediate of TRIF (TLR 3 and 4), MyD88 (TLR 7, 8, and 9), IPS-1 (Rig-I-like helicases, RLH)), and TBK1 or single-stranded RNA through TLR7 or TLR8 activates the gene expression of IFN-α and . The process involves the adaptor proteins MyD88, some kinases and transcription factor interferon regulatory factor (IRF) 7 [3, 4] . All of the pathways come to nuclear factor kappa B (NFκB). Moreover, the overproduction of IFN-α and by means of TMPD highly depends on TLR7-MyD88-IRF7 pathways.
Finally, the organ disorders reveal the manifestation of glomerulonephritis, pulmonary bleeding, and arthritis [4, 5] after the sufficient lupus-specific antibodies produced, such as anti-Sm, anti-RNP, anti-ribosomal P, anti-Su, anti-dsDNA, and antichromatin [6] [7] [8] .
Besides, according to Foncesa [9] and Janicahsvilli [10] , the pro-inflammatory cytokines dominantly exist and then result in systemic inflammation. Cash [11] also says that IL-6 is a targeted therapy which is potential for lupus. In contrary, the lupus patients do not experience excessive inflammation except the local joint inflammation when the flaring period happens. Deretic [12] and Zhu [13] explain the phenomenon that TMPD could lead to autophagy of the macrophages in vitro and in vivo in the spleen. There is no clear information about the impact of the autophagy on the innate and adaptive immune system. Thus, in this research, we observed IL-6, a proinflammatory cytokine produced by macrophages, in TMPD-treated lupus mice. IL-6 is suggested as a cytokine that has a direct role in the tissue damage [14] . The IL-6 which is produced by macrophages is CD68+IL-6. It was compared to the total IL-6 and then be correlated to the arthritis severity score of the knee joint of the mice.
Materials and methods

Materials
Female Balb/c mice aged 4 weeks were received from LPPT UGM. These mice were 
Methods
The experimental groups were a TMPD-treated group that was injected a volume of 0.5mL TMPD every 90 days (n=3) and a naïve group (n=3). The proteinuria measurement was done every 7 days. At the end of the experiment, mice were sacrificed.
Then, the fresh spleen cells were immediately prepared to be 2measured by using 
Results and discussion
Inflammation markers in lupus arthritis are potential biomarkers of lupus arthritis for drug development targets. Thus, it is a need to find markers that represent the disease severity. In this case, the pro-inflammatory marker IL-6 has a direct correlation to the tissue damage in spite of the macrophage autophagy in spleen which causes the inflammation decrease. This experiment discusses the phenomenon by means of the observation of the organoleptic data, the relative percentage of CD68+IL-6, the relative percentage of total IL-6, and the arthritis severity score (ASS) based on the Pritzker [15] scoring method.
In the organoleptic observation, the 6-month TMPD treated mice revealed a mild walking abnormality about 2-3 days and then the behavior normal the next day. There was no inflammation appeared in the joint, meanwhile the joint of the feet fingers seemed more red than normal. After the induction time over, the mice were sacrificed, and then the spleens were isolated. The spleen index was 227% than normal, reveals the functional disorder of the spleen as a secondary lymphoid organ. Table 1 and Table 2 .
The gate (R1) was decided in order to make a border to be applied to all samples in counting the IL-6 which is produced by macrophages. The chosen region was the monocytes and granulocytes region, so the counting was more specific. Figure 3 shows the increase of cell number and the increase of the number of CD68+IL-6 in the up-right (UR) region of the sample. It was analyzed and then the result is the significant increase (P<0.05) of the relative percentage of CD68+IL-6+.
Meanwhile, the total IL-6 is lower than the naïve mice. The decrease is not significant (P>0.05).
Both results were not in line, so we observed the outcome of the pathology processes to the joint of all mice. The results are shown in Figure 4 and Table 3 . The TMPD-treated mouse histology observation shows the erosion of hyaline layer in both bones. The erosion seems to be involved in the compact bone destruction in a long term.
The results lead to a prediction that dominant IL-6 in TMPD-treated lupus mice is IL-6 which is produced by macrophages (innate immune system). There are no differences of total IL-6 in both groups. According to the high grade of the arthritis severity score results in the TMPD-treated group, the IL-6 results seem not relevant. The score is significantly higher (P<0.05) than the naïve one. Moreover, the joint space logically shows the severity of inflammation in the joint. In this case, the mean of the joint spaces of both groups are not significantly different (P>0.05). It is predicted that the autophagy mechanism which is stated by Zhu [13] occurs, so the joint disorder develops without the equal increase of total IL-6. It might be a result of upregulation of TLR 3 on macrophages [16] causes the control of marker cells in rheumatoid diseases [17] .
The immune complex deposit could perform erosion of the hyaline layer of the joint [18, 19] and the imbalance of cytokines [20, 21] .
Conclusion
In conclusion, CD68+IL6 and ASS are the appropriate markers to investigate new drugs for lupus by using TMPD-treated mice. 
